The FDA first approved Eribulin on November 15, 2010, for the treatment of patients with metastatic breast cancer. Later, on January 28, 2016, FDA approved this drug for the treatment of unresectable and metastatic liposarcoma.

Eribulin was initially approved for metastatic (cancer that has spread to other parts of the body) or unresectable (cannot be removed with surgery) breast cancers not responding to anthracycline-based chemotherapy (a type of chemotherapy drug commonly used to treat various cancers). Recently, it gained FDA approval for liposarcoma treatment (a type of cancer originating from fat tissue), broadening its scope in addressing different types of cancer.

Eribulin is administered solely by healthcare professionals through intravenous injections (injected directly into your veins), typically in a hospital or clinical setting. It is available in two strengths: 0.88mg and 0.5mg. Your doctor will determine the appropriate dosage for you based on factors such as your age and overall health condition.

Like all medications, Eribulin may cause side effects, though not everyone will experience them. Eribulin may lead to severe side effects, including sepsis (a severe infection), severe allergic reactions, and serious skin conditions such as Stevens-Johnson syndrome. Common side effects include decreased white or red blood cell counts, fatigue, nausea, vomiting, constipation, diarrhea, numbness or tingling sensations, fever, loss of appetite, weight loss, difficulty breathing, cough, joint, muscle, back pain, headache, and hair loss. If you experience any of these symptoms, you must inform your healthcare provider promptly.

It is not recommended to take Eribulin if you are allergic to Eribulin or any of its other ingredients. Consult your doctor if you believe this applies to you. It is not recommended for children and adolescents younger than 18 years since the effects of Eribulin in this population are unknown. Before starting the treatment, you should inform your physician if you have fever, infections, liver, or heart problems. Before starting the treatment, give a detailed account of your medical history and medications.

When using Eribulin, you need to avoid its use if you are pregnant, as it may cause harm to the fetus. Similarly, refrain from using it while breastfeeding due to uncertainty about its passage into breast milk. If you have lung disorders, inform your doctor before starting treatment, as Eribulin may worsen symptoms. Those with liver problems should consult their doctor before starting treatment, as Eribulin can affect liver function. Limit alcohol intake while using Eribulin to reduce the risk of liver damage, as it contains small amounts of alcohol. Additionally, be cautious of tiredness and dizziness caused by Eribulin, as it may impair your ability to drive or operate machinery.

Your doctor will monitor your liver via blood tests and assess your heart function before and during treatment. If you are a woman who could become pregnant, ensure reliable birth control while taking Eribulin and for at least three months after stopping it. Consult your doctor for guidance on alternative contraception methods to avoid pregnancy during this treatment. Talk to your oncologist if you need dental treatment. Always tell your dentist you are having cancer treatment. This medicine can affect fertility in men  and women. If you are worried about this, it is important to talk with your doctor before you start treatment.

If you experience diarrhea while taking Eribulin, try to drink at least 2 liters of fluids daily and avoid alcohol, caffeine, milk products, and high-fat and high-fiber foods. If constipation occurs, increase your fluid intake, consume high-fiber foods, and engage in regular gentle exercise. Contact the hospital for advice; your doctor may prescribe laxatives to help constipation. If you notice a loss of appetite, don't worry if it lasts for a day or two, but if it persists or if you're losing weight, inform your nurse or dietitian for guidance. They may recommend supplements, dietary changes, or adjustments to eating habits to address these issues.

1. Eisai Europe Limited, Electronic medicines compendium (EMC), [Revised on Jan 2023] [Accessed on Feb 2024], https://www.medicines.org.uk/emc/files/pil.4517.pdf
2. Genentech, Inc, US Food and Drug Administration (FDA), [Revised on Jan 2016], [Accessed on Feb 2024], https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201532s015lbl.pdf
3. Goodman & Gilman's Pharmacological Basis of Therapeutics, Pharmacotherapy of neoplastic drugs, 13th edition, 2018, 1187.

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.